July 23, 2024 – Page 10 – Goldea Capital

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Patient dosing in the second cohort has commenced following the successful completion of the first cohort GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day), following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024. Cary...

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

Written by Customer Service on July 23, 2024. Posted in Public Companies.

DENVER, July 23, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S. Food and Drug Administration (FDA)-approved, patented cell-directed extracorporeal therapy to treat acute kidney injury (AKI) in pediatric patients weighing 10 kilograms or greater with sepsis or a septic condition requiring kidney replacement therapy (KRT). With this development, the Company has now met the August 20, 2024 FDA deadline to begin patient treatments, which is designated in the FDA’s approval of QUELIMMUNE. “This commercial milestone is highly gratifying to the SeaStar Medical team that has worked so hard to make QUELIMMUNE available to patients in need. Results from completed clinical trials show the potential...

FactSet Appoints Helen Shan as Chief Financial Officer

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Current FactSet Executive Goran Skoko to Take on Role of Chief Revenue Officer Company Reaffirms Full-Year Fiscal 2024 Guidance NORWALK, Conn., July 23, 2024 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced that Helen Shan, a seasoned FactSet executive who currently serves as Executive Vice President and Chief Revenue Officer, has been appointed Chief Financial Officer, effective immediately. Shan succeeds Linda Huber, who is transitioning out of the Company. Shan brings extensive financial leadership experience and business expertise within FactSet, and is rotating back into the CFO role, which she previously held from 2018 to 2021 before being appointed Executive Vice President and Chief Revenue Officer. As CFO,...

Blockchain Intelligence Group adds additional modules and launches its Certified Cryptocurrency Investigator – Advanced Series

Written by Customer Service on July 23, 2024. Posted in Public Companies.

VANCOUVER, British Colombia, July 23, 2024 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG, OTCQX: BBKCF, WKN: A2PS9W) is an established, diverse and innovative company operating globally in the Digital Asset, Blockchain and Metaverse sectors: Netcoins (Netcoins.com), Blockchain Intelligence Group (BlockchainGroup.io), and TerraZero (TerraZero.com). Blockchain Intelligence Group announces the launch of new CCI modules: Module 9 – Hacks & Exploits Module 10 – Compliance & Risk Management (Standalone Certification) Certified Cryptocurrency Investigator – Advanced Series (CCI-A) Blockchain Intelligence Group (BIG), a global leader in cryptocurrency investigations and compliance solutions, announces the launch of two new advanced modules for its acclaimed Certified Cryptocurrency...

ARHT Returns to the 3M Open with Interactive Holographic Experience in Minnesota

Written by Customer Service on July 23, 2024. Posted in Public Companies.

TORONTO, July 23, 2024 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT” or “the Company”) (TSXV: ART), (OTCQB: ARHTF) the global leader in the development, production, and distribution of high-quality, low latency hologram and digital content, is set to return with a dynamic interactive hologram experience at the prestigious 3M Open from July 22-28th, a highlight on the PGA Tour calendar held annually at TPC Twin Cities in Blaine, Minnesota. After a successful debut at the 3M Open in 2023, ARHT CAPSULE returns to the PGA Tour, showcasing its innovative capabilities to educate and engage attendees. The event will feature 360° interactive virtual content on the holographic display, challenging attendees to find and interact with numerous 3M products within two virtual locations: a golf course and homes, illustrating...

TIAN RUIXIANG Holdings Ltd Regains Compliance with Nasdaq’s Periodic Filing Requirement

Written by Customer Service on July 23, 2024. Posted in Public Companies.

BEIJING, July 23, 2024 (GLOBE NEWSWIRE) — TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the “Company”), a China-based insurance broker conducting business through its variable interest entity in China, today announced that the Company received a written notification from the Nasdaq Stock Market LLC (“Nasdaq”) on July 18, 2024, informing the Company that it has regained compliance with Nasdaq’s periodic filing requirement set forth under Listing Rule 5250(c)(1), because the Company had filed its annual report on Form 20-F for the period ended October 31, 2023 on July 17, 2024. About TIAN RUIXIANG Holdings Ltd TIAN RUIXIANG Holdings Ltd, headquartered in Beijing, China, is an insurance broker operating in China through its China-based variable interest entity. It distributes a wide range of insurance products,...

NANO Nuclear Energy Files Provisional Patents to Secure its Newly Acquired Annular Linear Induction Pump Technology

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Figure 1 The Annular Linear Induction Pump (ALIP) technology SBIR Phase III Program previously DOE funded $1.37Million in grants to support technology is led by Renowned Physicist and Carlos O. Maidana, Ph.D. The Annular Linear Induction Pump (ALIP) is a key enabling technology for NANO Nuclear’s ‘ODIN’ microreactor in development and the broader advanced nuclear reactor industry. New York, N.Y., July 23, 2024 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear”), a vertically integrated advanced nuclear energy and technology company developing portable clean energy solutions, today announced that it has filed a series of provisional patent applications with the United States Patent and Trademark Office (USPTO) to secure intellectual property rights for its recently acquired enabling annular linear induction...

Cannara Biotech Reports Q3 2024 Financial Results

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3 2023, a $5.6 million or 27.6%, increase. Total revenues, net of excise taxes, increased to $19.5 million in Q3 2024 from $15.9 million in Q3 2023, a $3.6 million or 22.6% increase. Delivered a thirteenth consecutive quarter of positive Adjusted EBITDA1 of $2.8 million. All financial results are reported in Canadian dollars, unless otherwise stated. MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara” or the “Company“) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced its fiscal third quarter...

Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel

Written by Customer Service on July 23, 2024. Posted in Public Companies.

Paves the Way for Kane’s revyve™ Antimicrobial Wound Gel Spray WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA) has eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel (“revyve™”). Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could be administered to patients. This now clears the way for the introduction and extended use of Kane’s revyve™ Antimicrobial Wound Gel Spray which is expected to be filled in spray cans in a higher quantity making it ideal for application on large wounds. “This is yet another important development for Kane as it allows...

Bombardier intends to vigorously defend itself after the Superior Court of Québec partially authorized the institution of a class action related to its Restricted Share Unit Plan

Written by Customer Service on July 23, 2024. Posted in Public Companies.

MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier” or the “Company”) announced that it intends to vigorously defend itself against a class action which the Superior Court of Québec only partially authorized Plaintiff Jérôme Gauthier to institute against it (the “Authorization Decision”). Bombardier denies any wrongdoing. As previously disclosed, on April 21, 2023, an application for authorization to institute a class action was filed before the Superior Court of Québec, in the district of Montréal, against Bombardier and Messrs. Pierre Beaudoin, Éric Martel and Alain Bellemare (respectively, the Chairman of the Board of Directors, the President and Chief Executive Officer and the former President and Chief Executive Officer of Bombardier) (the “Application”). The Application...

Day: July 23, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice